Maze, D., Arcasoy, M. O., Henrie, R., Cerquozzi, S., Kamble, R., Al-Hadidi, S., … Gupta, V. (2024). Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant, 59(2), 295. https://doi.org/10.1038/s41409-023-02194-y

Maze, Dawn, Murat O. Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble, Samer Al-Hadidi, Abdulraheem Yacoub, et al. “Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.” Bone Marrow Transplant 59, no. 2 (February 2024): 295. https://doi.org/10.1038/s41409-023-02194-y.

Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, et al. Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 Feb;59(2):295.

Maze, Dawn, et al. “Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.” Bone Marrow Transplant, vol. 59, no. 2, Feb. 2024, p. 295. Pubmed, doi:10.1038/s41409-023-02194-y.

Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 Feb;59(2):295.